-
Mashup Score: 0Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma - 21 day(s) ago
Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma - 23 day(s) ago
Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma - 28 day(s) ago
Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Sagar Lonial, MD, FACP, details how CAR T-cell therapies and off-the-shelf treatments are improving outcomes for patients with multiple myeloma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma @DanaFarber #mmsm #oncology #MedTwitter https://t.co/4JCvZrXEoA